Carbaglu Tablet, For Suspension
Product Images NDC 52276-312

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Carbaglu (NDC 52276-312). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Recordati Rare Diseases, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carbaglu Structure (1)

Chemical structure of Carglumic Acid showing its molecular composition with functional groups including amino, carboxyl, and hydroxyl moieties.*

FDA Label Image

Ammonia Response Chart (2)

A line graph titled NH3 response showing mean NH3 levels (µmol/L) over time from baseline to long-term in 13 evaluable patients. The x-axis represents days, including Baseline, Day 2, Day 4, Day 6, and Long-term, while the y-axis measures mean NH3 levels. The graph shows a sharp decrease in mean NH3 levels from baseline to Day 2, followed by a relatively stable low level through Day 6 to long-term.*

FDA Label Image

Rrd Logo (8)

FDA Label Image

Carbaglu 5 Box 4022646

Carbaglu 200 mg tablets for oral suspension packaging label. The label shows the product name, strength, and dosage form, with instructions to disperse tablets in water without swallowing whole or crushed. It indicates a package size of 5 tablets and includes storage directions and supplier information for Recordati Rare Diseases. The NDC number 52276-312-05 is displayed, along with barcode and lot information.*

FDA Label Image

Carbaglu 5 Label 4022647

Carbaglu 200 mg tablets for oral suspension packaging label from Recordati Rare Diseases. The label shows the product name, strength, dosage form, NDC 52276-312-05, quantity of 5 tablets, and usage instructions including discard one month after first opening. The manufacturer and distributor details are also present.*

FDA Label Image

Carbaglu 60 Box 4022648

Carton packaging label for Carbaglu 200 mg tablets for oral suspension, containing 60 tablets. The label shows the proprietary name Carbaglu with the generic name carglumic acid, dosage form as tablets for oral suspension, and strength of 200 mg. Labeler and distributor are Recordati Rare Diseases, Inc., Lebanon, NJ, USA, and Recordati Rare Diseases, Puteaux, France. Includes directions on tablet dispersion and storage instructions.*

FDA Label Image

Carbaglu 60 Label 4022649

Carbaglu 200 mg tablets for oral suspension packaging label displays the product name, active ingredient carglumic acid, and a quantity of 60 tablets. The label includes instructions to discard one month after first opening, storage conditions, NDC 52276-312-60, and the Recordati Rare Diseases logo. It also shows barcode and expiration and lot number fields. The labeler is Recordati Rare Diseases.*

FDA Label Image

Figure 2

A line graph showing the proportion of events (%) on the y-axis over time in days on the x-axis for two groups: CARBAGLU treatment (solid line) and placebo (dotted line). The graph illustrates comparative event proportions for these groups over a 6-day period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.